Topic 24

antibodies neutralizing antibody vaccine spike cov sars immunology against vaccines epitopes neutralization virus covid rbd 19 binding epitope infection receptor pandemic viral monoclonal immune antigen domain glycoprotein vaccination immunity responses convalescent potent protective ace2 coronavirus protein humoral design immunization protection igg titers immunogenicity immunized elicited development antigenic effective antigens affinity candidate recombinant sera immunogenic response neutralize microbiology human trimer respiratory therapeutic serum cd8 peptide infected candidates hiv prophylactic s1 anti safe entry potently efficacy target specific antigenicity targeting fusion viruses mice influenza severe cd4 global cross authentic conformation subunit trimeric reactive prefusion broadly challenge mabs nucleocapsid promising plasma urgently glycan

457 items. Top items listed below.

Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement 36 24 1

Preclinical study of DNA vaccines targeting SARS-CoV-2 24 1

Potent neutralizing antibodies in the sera of convalescent COVID-19 patients are directed against conserved linear epitopes on the SARS-CoV-2 spike protein 24 1

A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability 36 24 1

Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections 24 1

Cross-sectional evaluation of humoral responses against SARS-CoV-2 Spike 24 1

A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses 24 1

The receptor binding domain of SARS-CoV-2 spike is the key target of neutralizing antibody in human polyclonal sera. 24 1

SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses 24 1

The immunodominant and neutralization linear epitopes for SARS-CoV-2 24 1

Neutralizing Antibodies Isolated by a site-directed Screening have Potent Protection on SARS-CoV-2 Infection 24 1

Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2 24 1

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody 24 1

A single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against SARS-CoV-2 in mice 24 1

Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies 36 24 1

SARS-CoV-2-induced humoral immunity through B cell epitope analysis and neutralizing activity in COVID-19 infected individuals in Japan 24 1

Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual 24 1

A simple protein-based surrogate neutralization assay for SARS-CoV-2 36 24 1

Characterization of neutralizing versus binding antibodies and memory B cells in COVID-19 recovered individuals from India 24 1

A valid protective immune response elicited in rhesus macaques by an inactivated vaccine is capable of defending against SARS-CoV-2 infection 24 1

Potent human neutralizing antibodies elicited by SARS-CoV-2 infection 24 1

Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals 24 1

Tiger team: a panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes 24 1

Mapping the Immunodominance Landscape of SARS-CoV-2 Spike Protein for the Design of Vaccines against COVID-19 24 1

SARS-CoV-2 assays to detect functional antibody responses that block ACE2 recognition in vaccinated animals and infected patients 24 1

Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies 24 1

Rapid Development of Neutralizing and Diagnostic SARS-COV-2 Mouse Monoclonal Antibodies 24 1

Single-dose intranasal administration of AdCOVID elicits systemic and mucosal immunity against SARS-CoV-2 in mice 24 1

Modified Vaccinia Ankara Based SARS-CoV-2 Vaccine Expressing Full-Length Spike Induces Strong Neutralizing Antibody Response 24 1

Insight into vaccine development for Alpha-coronaviruses based on structural and immunological analyses of spike proteins 24 1

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability 24 1

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody 24 1

Potent Neutralizing Antibodies Directed to Multiple Epitopes on SARS-CoV-2 Spike 24 1

Structural and functional analysis of a potent sarbecovirus neutralizing antibody 24 1

A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein 24 1

Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals 24 1

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants 24 1

SARS-CoV-2 infection severity is linked to superior humoral immunity against the spike 24 1

Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis 36 24 1

Multi-Clonal Live SARS-CoV-2 In Vitro Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors 24 1

Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model 24 1

A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV 24 1

Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding 24 1

The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement 24 1

Potential T-cell and B-cell Epitopes of 2019-nCoV 191 76 24 1

SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development 24 1

Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection 24 1

A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2 24 1

Monoclonal antibodies for the S2 subunit of spike of SARS-CoV cross-react with the newly-emerged SARS-CoV-2 36 1

Tissue-resident memory CD8 T-cell responses elicited by a single injection of a multi-target COVID-19 vaccine 24 1

SARS-CoV-2 Elicits Robust Adaptive Immune Responses Regardless of Disease Severity 24 1

Antibody repertoire induced by SARS-CoV-2 spike protein immunogens 24 1

SARS-CoV-2 Neutralizing Antibody Responses Are More Robust in Patients with Severe Disease 24 1

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein 24 1

The influence of major S protein mutations of SARS-CoV-2 on the potential B cell epitopes 24 1

NeutrobodyPlex - Nanobodies to monitor a SARS-CoV-2 neutralizing immune response 24 1

Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection 24 1

Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation 24 1

SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface 24 1

Bivalent binding of a fully human IgG to the SARS-CoV-2 spike proteins reveals mechanisms of potent neutralization 24 1

Single-dose replicating RNA vaccine induces neutralizing antibodies against SARS-CoV-2 in nonhuman primates 24 1

Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals 24 1

Development of a Synthetic Poxvirus-Based SARS-CoV-2 Vaccine 24 7 1

IgA MAb blocks SARS-CoV-2 Spike-ACE2 interaction providing mucosal immunity 24 1

Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples 130 24 1

Robust neutralization assay based on SARS-CoV-2 S-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressed BHK21 cells 36 24 1

Fully human single-domain antibodies against SARS-CoV-2 24 1

Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent COVID-19 patients. 191 24 1

High-throughput detection of antibodies targeting the SARS-CoV-2 Spike in longitudinal convalescent plasma samples 24 1

Isolation of and Characterization of Neutralizing Antibodies to Covid-19 from a Large Human Naìˆve scFv Phage Display Library 24 1

Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition 24 1

Ex vivo detection of SARS-CoV-2-specific CD8+ T cells: rapid induction, prolonged contraction, and formation of functional memory 24 1

S protein-reactive IgG and memory B cell production after human SARS-CoV-2 infection includes broad reactivity to the S2 subunit 24 1

High titers of multiple antibody isotypes against the SARS-CoV-2 spike receptor-binding domain and nucleoprotein associate with better neutralization. 130 24 1

Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection 24 1

Cross-neutralization antibodies against SARS-CoV-2 and RBD mutations from convalescent patient antibody libraries 36 24 1

Characterization of cells susceptible to SARS-COV-2 and methods for detection of neutralizing antibody by focus forming assay 24 1

Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1) Formulated with Aluminum Hydroxide Induces Protective Immunity and Reduces Immune Enhancement 24 1

Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates 24 1

Extremely potent human monoclonal antibodies from convalescent Covid-19 patients 24 1

Immunogenicity of novel mRNA COVID-19 vaccine MRT5500 in mice and non-human primates 24 1

mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2 191 36 24 1

Designing of Epitope-Based Vaccine from the Conserved Region of the Spike Glycoprotein of SARS-CoV-2 191 76 24 1

The landscape of antibody binding to SARS-CoV-2 24 1

Zebrafish studies on the vaccine candidate to COVID-19, the Spike protein: Production of antibody and adverse reaction 24 1

Rapid selection of a human monoclonal antibody that potently neutralizes SARS-CoV-2 in two animal models 24 1

Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses 24 1

Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike protein 24 1

A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses 24 1

Identification of neutralizing human monoclonal antibodies from Italian Covid-19 convalescent patients 24 1

Monoclonal Antibodies Capable of Binding SARS-CoV-2 Spike Protein Receptor Binding Motif Specifically Prevent GM-CSF Induction. 36 1

Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2 24 1

Attenuated influenza virions expressing the SARS- CoV-2 receptor-binding domain induce neutralizing antibodies in mice 24 1

Structural Basis for Potent Neutralization of Betacoronaviruses by Single-domain Camelid Antibodies 24 1

Evidence of antigenic imprinting in sequential Sarbecovirus immunization 24 1

A single dose of recombinant VSV-{triangleup}G-spike vaccine provides protection against SARS-CoV-2 challenge 24 1

LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection 24 1

A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model 24 1

Spike protein binding prediction with neutralizing antibodies of SARS-CoV-2 1

BANCOVID, the first D614G variant mRNA-based vaccine candidate against SARS-CoV-2 elicits neutralizing antibody and balanced cellular immune response 24 1